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sitivity of 58% and specificity of 91% for identifying lesion type B2+C by ACC/AHA guide line. 
Conclusion: Direction and velocity of baseline coronary flow using transthoracic Doppler 
echocardiography provide clinically valuable informations about the condition of coronary 
artery. Especially, slow flow predicts the pathologic flow dynamics of coronary art~des. 
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1201-79 Long-Term Prognostic Value of Triiodothyronine 
Concentration in Elderly Patients With Stable Heart 
Fai lure 
Jairo Rays, Mauricio Wajngarten, Otavio E. Gebara, Amit Nussbecher, Joao Batista 
Serro Azul, Humberto Pierri, Heart Institute, S~o Paulo, Brazil. 
Background : Heart Failure (HF) is very prevalent in eidedy patients. Low total triiodothyro- 
nine (T3), with normal free thyroxine (FT4) and thyroid stimulating hormone (TSH) concen- 
trations is frequent and has prognostic value in severely ill patients. However, this hormonal 
milieu has not been studied in elderly patients with stable HIE Objective: To investigate the 
prognostic value of T3 concentration in elderly patients with stable HF and without thyroid 
disease. Methods : We evaluated 69 elderly patients with stable NYHA class II-lll HF, with 
FT4 and TSH within normal range. Patients were followed by an average of 14±8 months 
and had T3 concentration analyzed. 44 age matched subjects without ventricuier dysfunc- 
tion formed the control group. Results : HF patients had significantly lower T3 concentration 
than controls (89±23 vs 101±16 ng/dl, p-~.0098). Among HF patients that died, T3 concen- 
tration was lower than of those who survived (79.t.22 vs 93¢2.3 ng/dl, p=0.03). Furthermore, 
mortality was higher in patients with levels of T3 bower than 80ng/dl (figure). The adjusted 
odds.ratio for cardiovascular events (hospitalization and/or death) was 9.8 (95% CI 2.2 to 
43.0; p=0.004) for patients with T3 concentration lower than 80ng/dl versus those with T3 
between 80 and 100 rig/d1. Conclusion : In eldedy patients with stable HF and without thy- 
roid disease, T3 concentration lower than 80ng/dl is associated with worse prognosis. T3 
values should be included in the routine evaluation of this population. 
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1201-80 The Predictive Value of Combinations of Different 
Levels of Brain Natr iuret ic  Pept ide and Norepinephrine 
in the  VaI -HeFr  Trial 
Inderiit S. Anand. Roberto Latini, Serge Masson, Dienne Judd, Aido P. Maggioni, Robert 
Glazer, Tom Chiang, Philippe Lechat, Gianni Tognoni, Jay N. Cohn, on the behalf of the 
VaI-HeFT Investigators, VA Medical Center and University of Minnesota, Minneapolis, 
Minnesota, Istituto di Ricerche Farmacologiche, Milan, Italy: 
Background: Plasma brain natriuretic paptide (BNP) and plasma norepinephrine (NE) 
are important markers of the severity and prognosis of heart failure (HF). Whether any 
combination of BNP and NE has additional prognostic value has never been reported. 
Methods and Results: The VaI-HeFT trial evaluated the efficacy of the angiotensin 
receptor blocker valsartan in 5010 patients with HF, and measured BNP and NE at base- 
line. Patients were stratified based on background beta-blocker (BB) therapy. 93% 
patients were receiving ACE-I and 35 % BB at baseline. BNP and NE (both in pg/mL) 
were measured in core labs. The mortality risk was calculated in various combinations 
depending on the median value of BNP (97 pg/mL) and NE (394 og/mL), with BNP and 
NE defined as high (->) or low (<) for values above and below the median. As expected, 
high values of BNP or NE were associated with a significantly higher mortality. The risk 
ratios for various combinations of BNP and NE in order of magnitude are shown in the 
Table. Conclusions: Whereas both plasma BNP and NE are significant prognostic mark- 
ers in HF, plasma BNP is the stronger of the two. High NE contributes greater prognostic 
value in the presence of high than low BNP. 
*RR from Cox proportional hazard model; **p-value calculated from Io~ rank dest 
Subgroup Comparison Group 1 (n) Group2 (n) Risk Ratio* 95 % C.I. p-value** 
_>BNP vs <BNP 2171 2134 2.08 1.79, 2.42 <0.0001 
>NE vs <NE 2151 2150 1.48 1.28, 1.71 <0.0001 
_>BNP + >NE vs <BNP + <NE 1223 1206 2.79 2.25,3.47 <0.0001 
_>BNP + <NE vs <BNP + <NE 935 1206 1.93 1.54, 2.43 <0.0001 
<BNP + ->NE vs <BNP + <NE 920 1206 1.27 0.99, 1.63 0.0056 
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1201-81 N-Terminal Pro Brain Natrlureti¢ Peptide (NT-proBNP) 
Predicts Left Ventriculer Function and Mortality in 
Hemodlalysis Patients but Not Cardiac Death: A Two- 
Year Outcome Study 
Joseoh P. Lonohitano. William L. Henhch, Paul D. Light, Eric Tiblier, Heidi Sparger, 
Mathew M. Smilay, John Badalamenti, Juergen Trawinski, Christopher R. deFilippi, 
University of Maryland, Baltimore, Maryland, University of Texas Medical Branch, 
Galveston, Texas. 
NT-proBNP is a stable marker of left ventricular (LV) dysfunction in the general popula- 
tion, but its predictive value in patients on chronic hemodialysis (HD), a group with 
chronic volume overload as well as a large burden of ischemic heart disease and cardio- 
vascular death, is unknown. This prospective study of 224 HD patients was designed to 
learn the predictive value of NT-proBNP for death, LV function and the magnitude of 
CAD. HD pts from 5 HD centers (age 60±15 years, 54% male, 48% diabetic) in whom 
NT-proBNP levels (mean of two values, one month apart, normal <70 pmol/L, Roche 
Diagnostics), LVEF and LV mass (measured by echocardiography in 155 of 224 pts) 
were quantified. For the 77 pts who died during the 2 year fonow-up, NT-proBNP levels 
were significantly higher than in those who lived (7027±8660 vs. 4613+5921, p=0.015). 
For the 24 pts with LVEF_< 0.40, NT-preBNP levels were higher than pts with LVEF >0.40 
(9956±11420 vs. 4853±5940, p=0.0013). The Table depicts NT-proBNP by quartiies, and 
shows the corresponding mortality (%), depressed LVEF (%), mean LV mass, multives- 
sel CAD (%) and cardiac death or non-fatal MI (%). Overall mortality, LV dysfunction and 
LV mass increased with risifig NT-proBNP levels but NT-proBNP was not predictive of 
multivessel CAD or cardiac death. 
We conclude that NT-proBNP levels are high in most HD pts, and that levels >2800 pmol/ 
L are associated with a marked decrease in LVEF and risk of all cause mortality in a large 
percentage of pts but are not a marker of atheroscierotic burden or CV death, 
Quartile 1 Quartile 2 Quartile 3 Quartile 4 pvaluefortrend 
NT-proBNP (pmol/L) 87-1246 1247-27662792-66986730-55164 
Death (% pts) 23.2 23.2 46.4 44.6 0.006 
LVEF< 0.40 (% pts) 2.6 9.8 22.6 27.3 0.008 
LV mass (g/m 2) 130-~31 133+31 137±44 160±39 0.002 
Multivessel CAD (% pts) 42.1 18.1 5.6 47.6 0.790 
CV Death or Non-Fatal MI 16.1 17.9 16.1 22.6 0.450 
(% pts) 
1201-82 Effect of Combined Hormone Replacement Therapy on 
Thrombotic and Fibrinolytic Potentials and Lp(a) Levels 
in Elderly Women 
Otavio C. Gebara, Margareth Venturinell, Jose M. Aldrighi, Nubia Vieira, Amit 
Nussbacher, Humberto Pierri, Serro-Azul Jo~o, Elbio D'Amico, Mauricio Wajngarten, 
Giuseppe Rosano, Jose A. Ramiras, Heart Institute from the Medical School University 
of S~o Paulo, Sao Paulo, Brazil, Instituto San Raffaelle, Rome, Italy: 
Background: Eldedy women are are potential candidates for postmenopausal hormone 
replacement herapy (HRT). This therapy, however, may increase their risk of thrombotic 
cardiovascular events. To date, the impact of HRT on coagulation, fibrinolysis, and levels 
of lipoprotein (a) [Lp(a)] is not fully understood in this population. 
Method~ In a double-blind, placebo-controlled study, 17 women older than 65 years 
(mean age 70_+4 yrs),without cardiovascular disease,received for a period of 60 days 
either HRT (oral conjugated estrogens 0,625 mg/d plus medrexyprogesterone acetate 
2,5mg/d) or placebo. At the and of each treatment phase, we measured variables that 
express a pro-thrombotic state (fibdnogen, factor VII, vonWillebrand factor [vWF], anti- 
thrembin III [ATIII], Protein C), or that express activation of coagulation (thrombin-anti- 
thrombin complex[TAT] and fragment 1+2[F1.2] ), and variables that show activation of 
fibrinolysie (t-PA activity [t-PAac], t-PA antigen, t-PA inhibitor [PAl-l], Lp(a) and D-dimar). 
Conclusion: HRT in elderly women increased markers of thrombosis and increased the 
fibdnolytic potential. The clinical significance of these opposing effects should be evalu- 
ated in prospective studies and may be important in better selecting candidates for long- 
term treatment. 
Results: HRT Placebo P 
Fibrinogen (mg/dl) 326+79 315+64 0.618 
Factor VII (%) 136+45 151+39 0.250 
vWF (%) 117+ 13 116+ 15 0.908 
ATIII (%) 143+35 139+30 0.672 
Protein C (%) 116+36 111+31 0.608 
TAT (mg/L) 4.7+2.1 3.4+0.9 0.016 
F1+2 (nmol/L) 3.0+2.8 1.4+0.6 0.018 
t-PAac (UI/mL) 43+13 34+9 0.001 
t-PAag (ng/ml) 5.6+1.6 6.5+1.7 0.014 
PAl-1 (ng/ml) 24.0+6.9 25.6+9.1 0.775 
D-dimer (ng/ml) 85+62 57+37 0.023 
Lp(a)(ng/ml) 19.1+14.5 29.0+22 0.025 
